NCT02795546View on ClinicalTrials.gov

Effect of Alendronate With β - TCP Bone Substitute in Surgical Therapy of Periodontal Intra-osseous Defects.

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Intrabony Periodontal Defect
Interventions
DRUG

Alendronate sodium

400µg of alendronate sodium is combined with beta-tricalcium phosphate bone graft and implanted in periodontal intra-osseous defects as a single, local dose.

BIOLOGICAL

beta-tricalcium phosphate bone substitute

beta-tricalcium phosphate bone graft is implanted in periodontal intra-osseous defects.

All Listed Sponsors
lead

Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre

OTHER

NCT02795546 - Effect of Alendronate With β - TCP Bone Substitute in Surgical Therapy of Periodontal Intra-osseous Defects. | Biotech Hunter | Biotech Hunter